Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells

Cited by (885)

Items 301–400 of 885

1. Evaluation of the siRNA PF-04523655 versus Ranibizumab for the Treatment of Neovascular Age-related Macular Degeneration (MONET Study)
   Quan Dong Nguyen, Ronald A. Schachar, Chudy I. Nduaka, Marvin Sperling, Karen J. Klamerus, Katherine Chi-Burris, Eric Yan, Dario A. Paggiarino, Irit Rosenblatt, Roger Aitchison et al. · 2012 · Ophthalmology
2. Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression
   Yung‐Wu Chen, Morey L. Smith, Michael P. Sheets, Steve J. Ballaron, James M. Trevillyan, Sandra E. Burke, Teresa A. Rosenberg, Cindy L. Henry, Rolf Wagner, Joy L. Bauch et al. · 2007 · Journal of Cardiovascular Pharmacology
3. Feeding an army: The metabolism of T cells in activation, anergy, and exhaustion
   Greg M. Delgoffe, Jonathan D. Powell · 2015 · Molecular Immunology
4. The homeostatic regulation of ribosome biogenesis
   Chunyang Ni, Michael Buszczak · 2022 · Seminars in Cell and Developmental Biology
5. Inhibitory Effect of Rapamycin on Corneal Neovascularization In Vitro and In Vivo
   Young-Sam Kwon, Hyun Sook Hong, Jae Chan Kim, Jun‐Seop Shin, Youngsook Son · 2005 · Investigative Ophthalmology & Visual Science
6. Group I metabotropic glutamate receptors activate the p70S6 kinase via both mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK 1/2) signaling pathways in rat striatal and hippocampal synaptoneurosomes
   Guylène Page, Fuad Al Khidir, Stéphanie Pain, Laurence Barrier, Bernard Fauconneau, Olivier Guillard, Alain Piriou, Jacques Hugon · 2006 · Neurochemistry International
7. mTOR: A Potential Therapeutic Target in Osteoarthritis?
   Bandna Pal, Helal Endisha, Y. Zhang, Mohit Kapoor · 2015 · Drugs in R&D
8. The Rapamycin and FKBP12 Target (RAFT) Displays Phosphatidylinositol 4-Kinase Activity
   David M. Sabatini, Brian A. Pierchala, Roxanne K. Barrow, Michael J. Schell, Solomon H. Snyder · 1995 · Journal of Biological Chemistry
9. mTORC1‐ and mTORC2‐interacting proteins keep their multifunctional partners focused
   Ismael Bracho‐Valdés, Paola Moreno‐Alvarez, Israel Valencia‐Martínez, Evelyn Robles‐Molina, Lydia Chávez‐Vargas, José Vázquez‐Prado · 2011 · IUBMB Life
10. Zona Occludens-2 Inhibits Cyclin D1 Expression and Cell Proliferation and Exhibits Changes in Localization along the Cell Cycle
    Rocío Tapia, Miriam Huerta, Socorro Islas, Antonia Ávila‐Flores, Esther López‐Bayghen, Jörg Weiske, Otmar Huber, Lorenza González‐Mariscal · 2008 · Molecular Biology of the Cell
11. Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans
    D. Scott Snyder, Pamela L. C. Small · 2003 · Microbial Pathogenesis
12. Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface
    Shigdel, Uddhav K., Lee, Seung-Joo, Sowa, Mathew E., Bowman, Brian R., Robison, Keith, Zhou, Minyun, Pua, Khian Hong, Stiles, Dylan T., Blodgett, Joshua A. V., Udwary, Daniel W. et al. · 2020 · Proceedings of the National Academy of Sciences
13. TOR Signaling in Fission Yeast
    Yoko Otsubo, Masayuki Yamamato · 2008 · Critical Reviews in Biochemistry and Molecular Biology
14. Protein Kinase Activity and Identification of a Toxic Effector Domain of the Target of Rapamycin TOR Proteins in Yeast
    Clara M. Alarcón, Joseph Heitman, Maria Elena Cardenas · 1999 · Molecular Biology of the Cell
15. Neural roles of immunophilins and their ligands
    David M. Sabatini, Michael Min-Shyue Lai, Solomon H. Snyder · 1997 · Molecular Neurobiology
16. Clinical development of mammalian target of rapamycin inhibitors
    Janet Ellen Dancey · 2002 · Hematology/Oncology Clinics of North America
17. The molecular basis of mTORC1-regulated translation
    Carson C. Thoreen · 2017 · Biochemical Society Transactions
18. Carboxyl‐terminal region conserved among phosphoinositide‐kinase‐related kinases is indispensable for mTOR function in vivo and in vitro
    Tetsuya Takahashi, Kenta Hara, Hitomi Inoue, Yoshitaka Kawa, Chiharu Tokunaga, Hidayat Sujuti, Kenichi Yoshino, Yoshikazu Kuroda, Kazuyoshi Yonezawa · 2000 · Genes to Cells
19. Target of rapamycin (TOR) signaling controls epithelial morphogenesis in the vertebrate intestine
    Khadijah Makky, Jackie Tekiela, Alan N. Mayer · 2006 · Developmental Biology
20. Genetic Variability of the mTOR Pathway and Prostate Cancer Risk in the European Prospective Investigation on Cancer (EPIC)
    Daniele Campa, Anika Hüsing, Angelika Stein, Lucie Dostal, Heiner Boeing, Tobias Pischon, Anne Marie Tjønneland, Nina Roswall, Kim Overvad, Jane Nautrup Østergaard et al. · 2011 · PLoS ONE
21. Ataxia-telangiectasia and the ATM gene: Linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints
    Yosef Shiloh, Galit Rotman · 1996 · Journal of Clinical Immunology
22. Rapamycin Inhibits Proliferation of Epstein-Barr Virus–Positive B-cell Lymphomas Through Modulation of Cell-Cycle Protein Expression
    Maria Vaysberg, Cynthia E. Balatoni, Ronald R. Nepomuceno, Sheri M. Krams, Olivia M. Martinez · 2007 · Transplantation
23. Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?
    Elisabetta Rovida, Barbara A. Stecca · 2015 · Seminars in Cancer Biology
24. Drug discovery targeting the mTOR pathway
    Alberto Maria Martelli, Francesca Buontempo, James Andrew McCubrey · 2018 · Clinical Science
25. Platelet‐derived growth factor stimulates LAT1 gene expression in vascular smooth muscle: Role in cell growth
    Xiaoming Liu, Sylvia V. Reyna, Diana Ensenat, Kelly J. Peyton, Hong Wang, Andrew I. Schafer, William Durante · 2004 · The FASEB Journal
26. Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice
    Charlotte Hinault, Isabelle Mothe‐Satney, Nadine Gautier, John C. Lawrence, Emmanuel VAN OBBERGHEN · 2004 · The FASEB Journal
27. Protein Kinase C-δ and Phosphatidylinositol 3-Kinase/Akt Activate Mammalian Target of Rapamycin to Modulate NF-κB Activation and Intercellular Adhesion Molecule-1 (ICAM-1) Expression in Endothelial Cells
    Mohd Minhajuddin, Kaiser M. Bijli, Fabeha Fazal, Antonella Sassano, Keiichi I. Nakayama, Nissim Hay, Leonidas C. Platanias, Arshad Rahman · 2008 · Journal of Biological Chemistry
28. Rapamycin specifically interferes with the developmental response of fission yeast to starvation
    Ronit Weisman, Mordechai Choder, Yigal Koltin · 1997 · Journal of Bacteriology
29. Mammalian target of rapamycin
    Funda Meric‐Bernstam · 2004 · Seminars in Oncology
30. Polycystic kidney disease: Pathogenesis and potential therapies
    Vinita Takiar, Michael J. Caplan · 2010 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
31. Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson’s Disease
    Rosalba Siracusa, Irene Paterniti, Marika Cordaro, Rosalia Crupi, Giuseppe Bruschetta, Michela Campolo, Salvatore Cuzzocrea, Emanuela Esposito · 2017 · Molecular Neurobiology
32. Diverse structures, functions and uses of FK506 binding proteins
    Julia Maeve Bonner, Gabrielle L. Boulianne · 2017 · Cellular Signalling
33. The Architecture of the Rag GTPase Signaling Network
    Raffaele Nicastro, Alessandro Sardu, Nicolas Panchaud, Claudio DE VIRGILIO · 2017 · Biomolecules
34. A Unified Total Synthesis of the Immunomodulators (−)-Rapamycin and (−)-27-Demethoxyrapamycin: Construction of the C(21−42) Perimeters
    Amos B. Smith, Stephen M. Condon, John A. McCauley, Johnnie L. Leazer, James W. Leahy, Robert E. Maleczka · 1997 · Journal of the American Chemical Society
35. Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
    Burnett, G. Leslie, Yang, Yu C., Aggen, James B., Pitzen, Jennifer, Gliedt, Micah K., Semko, Chris M., Marquez, Abby, Evans, James W., Wang, Gang, Won, Walter S. et al. · 2023 · Journal of Medicinal Chemistry
36. Two Distinct Controls of Mitotic Cdk1/Cyclin B1 Activity Requisite for Cell Growth Prior to Cell Division
    Toru Miyazaki, Satoko Arai · 2007 · Cell Cycle
37. Regulated expression of the Leishmania major surface virulence factor lipophosphoglycan using conditionally destabilized fusion proteins
    Luciana Madeira da Silva, Katherine L. Owens, Silvane Maria Fonseca Murta, Stephen M. Beverley · 2009 · Proceedings of the National Academy of Sciences
38. Influence of age on rat bone-marrow mesenchymal stem cells potential
    Juan Fafián‐Labora, Pablo Fernández‐Pernas, I.M. Fuentes, Francisco Javier de Toro Santos, Natividad Oreiro, Susana Sangiao‐Alvarellos, Jesús Mateos, María C. Arufe · 2015 · Scientific Reports
39. Urolithin B, a Newly Identified Regulator of Skeletal Muscle Mass
    Rodriguez, Julie, Pierre, Nicolas, Naslain, Damien, Bontemps, Françoise, Ferreira, Daneel, Priem, Fabian, Deldicque, Louise, Francaux, Marc · 2017 · Journal of Cachexia Sarcopenia and Muscle
40. mTOR Signaling in Cancer Cell Motility and Tumor Metastasis
    Hongyu Zhou, Shile Huang · 2010 · Critical Reviews in Eukaryotic Gene Expression
41. Control of B lymphocyte development and functions by the mTOR signaling pathways
    Terri Iwata, Julita A. Ramírez, Heon Park, Brian M. Iritani · 2017 · Cytokine & Growth Factor Reviews
42. Chlorogenic acid inhibits proliferation and induces apoptosis in A498 human kidney cancer cells via inactivating PI3K/Akt/mTOR signalling pathway
    Xiaokang Wang, Jianghong Liu, Zhanxiong Xie, Jiaoyu Rao, Gengrui Xu, Kaiyuan Huang, Wenyan Li, Zijun Yin · 2019 · Journal of Pharmacy and Pharmacology
43. New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)
    Morris E. Feldman, Kevan M. Shokat · 2010 · Current topics in microbiology and immunology
44. The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC)
    Feliciano, David M. · 2020 · Frontiers in Neuroanatomy
45. Phas proteins as mediators of the actions of insulin, growth factors and cAMP on protein synthesis and cell proliferation
    John C. Lawrence, Patrick Fadden, Timothy Haystead, Tai-An Lin · 1997 · Advances in Enzyme Regulation
46. Expression, Enzyme Activity, and Subcellular Localization of Mammalian Target of Rapamycin in Insulin-Responsive Cells
    Dominic J. Withers, D. Margriet Ouwens, BARBARA T. NAVÉ, Gerard C.M. van der Zon, Clara M. Alarcón, Maria Elena Cardenas, Joseph Heitman, J. Antonie Maassen, Peter Robin Shepherd · 1997 · Biochemical and Biophysical Research Communications
47. The role of mTOR in age-related diseases
    Žofia Chrienová, Eugenie Nepovimová, Kamil Kuča · 2021 · Journal of Enzyme Inhibition and Medicinal Chemistry
48. Ex Vivo Rapamycin Generates Donor Th2 Cells That Potently Inhibit Graft-versus-Host Disease and Graft-versus-Tumor Effects via an IL-4-Dependent Mechanism
    Jason Foley, Unsu Jung, Angel Miera, Todd Borenstein, Jacopo Mariotti, Michael Eckhaus, Barbara E. Bierer, Daniel H. Fowler · 2005 · The Journal of Immunology
49. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity
    Òscar M. Tirado, Silvia Mateo‐Lozano, Vicente Notario · 2005 · Oncogene
50. TOR Action in Mammalian Cells and in Caenorhabditis elegans
    X. Long, Fritz Müller, Joseph Avruch · 2004 · Current topics in microbiology and immunology
51. Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway
    Andreas G. Bader, Katherine A. Felts, Ning Jiang, Hwai Wen Chang, Peter K. Vogt · 2003 · Proceedings of the National Academy of Sciences
52. Current Approaches and Future Directions for the Treatment of mTORopathies
    Vasiliki Karalis, Helen S. Bateup · 2021 · Developmental Neuroscience
53. Molecular actions of sirolimus: sirolimus and mTor
    Robert Arthur Kirken, Y.L Wang · 2003 · Transplantation Proceedings
54. Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy
    Abdelhakim Bouyahya, Aicha El Allam, Sara Aboulaghras, Saad Bakrim, Naoual El Menyiy, Mohammed Merae Alshahrani, Ahmed Abdullah Al Awadh, Taoufiq Benali, Learn−Han Lee, Nasreddine El Omari et al. · 2022 · Cancers
55. Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells
    Gina M. Yanochko, Walter Eckhart · 2006 · Breast Cancer Research
56. Inhibition of Mammalian Target of Rapamycin Potentiates Thrombin-Induced Intercellular Adhesion Molecule-1 Expression by Accelerating and Stabilizing NF-κB Activation in Endothelial Cells
    Mohd Minhajuddin, Fabeha Fazal, Kaiser M. Bijli, Md Ruhul Amin, Arshad Rahman · 2005 · The Journal of Immunology
57. Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or rapamycin
    Jing Chen, Nathan R. Wall, Kerry Kocher, Nicole Duclos, Doriano Fabbro, Donna S Neuberg, James D. Griffin, Yang Shi, Dwight Gary Gilliland · 2004 · Journal of Clinical Investigation
58. Preparation of a liposomal delivery system and its in vitro release of rapamycin
    Zhi-Lin Miao, Yingjie Deng, HONG-YANG DU, Xubin Suo, Xiaoyu Wang, Xiao Wang, Li Wang, LI-JIE CUI, Na Duan · 2015 · Experimental and Therapeutic Medicine
59. PI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?
    Yan Chen, Wei Guan, Meilan Wang, Xiaoyun Lin · 2024 · The International Journal of Neuropsychopharmacology
60. mTOR as a Target for Cancer Therapy
    Peter J. Houghton, Shile Huang · 2004 · Current topics in microbiology and immunology
61. The complex network of mTOR signalling in the heart
    Sebastiano Sciarretta, Maurizio Forte, Giacomo Frati, Junichi Sadoshima · 2021 · Cardiovascular Research
62. TOR-inhibitor insensitive-1 (TRIN1) regulates cotyledons greening in Arabidopsis
    Linxuan Li, Yun Song, Kai Wang, Pan Dong, Xueyan Zhang, Fuguang Li, Zhengguo Li, Maozhi Ren · 2015 · Frontiers in Plant Science
63. Calcineurin inhibitors and rapamycin: cancer protection or promotion?
    Maren Weischer, Martin Röcken, Mark Berneburg · 2007 · Experimental Dermatology
64. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways
    Michael Hahn, Weiqun Li, Chunrong Yu, Mohamed Rahmani, Paul Dent, Steven Grant · 2005 · Molecular Cancer Therapeutics
65. Constitutive Activation of S6 Kinase by Deletion of Amino-Terminal Autoinhibitory and Rapamycin Sensitivity Domains
    Malathy Mahalingam, Dennis J. Templeton · 1996 · Molecular and Cellular Biology
66. Structural mechanism of allosteric activation of TRPML1 by PI(3,5)P 2 and rapamycin
    Ninghai Gan, Yan Han, Weizhong Zeng, Yan Wang, Jing Xue, Youxing Jiang · 2022 · Proceedings of the National Academy of Sciences
67. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials
    Ana Isabel Sánchez-Fructuoso · 2008 · Expert Opinion on Drug Metabolism & Toxicology
68. Constitutively active Rheb induces oncogenic transformation
    Hao Jiang, Peter K. Vogt · 2008 · Oncogene
69. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies
    Robert H. Rubin, Tuija S Ikonen, Jan Fritz Gummert, Randall Ellis Morris · 1999 · Transplant Infectious Disease
70. A Novel Class of Dual-family Immunophilins
    Brian D. Adams, Alla Musiyenko, Rajinder Kumar, Sailen Barik · 2005 · Journal of Biological Chemistry
71. Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment
    Hongyu Wu, Hong Yao, Chen He, Yilin Jia, Zheying Zhu, Shengtao Xu, Dahong Li, Jinyi Xu · 2022 · Acta Pharmaceutica Sinica B
72. The Evolving Role of mTOR Inhibition in Transplantation Tolerance
    Gearoid Michael McMahon, Matthew R. Weir, X.C. Li, Didier A. Mandelbrot · 2011 · Journal of the American Society of Nephrology
73. Applying the Lessons of Tuberous Sclerosis: The 2015 Hower Award Lecture
    Ewell Steve Roach · 2016 · Pediatric Neurology
74. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of rapamycin in leukemic cells
    Matthias Mayerhofer, Karl J. Aichberger, Stefan Florian, Maria‐Theresa Krauth, Alexander W. Hauswirth, Sophia V. Derdak, Wolfgang R. Sperr, Harald Esterbauer, Oswald F Wagner, Christine Marosi et al. · 2005 · The FASEB Journal
75. Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity?
    Jennifer Bates, Lauri J. Diehl · 2013 · The Journal of Pathology
76. Pharmacological and Genetic Accumulation of Hypoxia-Inducible Factor-1α Enhances Excitatory Synaptic Transmission in Hippocampal Neurons through the Production of Vascular Endothelial Growth Factor
    Yu-Fei Huang, Chih‐Hao Yang, Chiung‐Chun Huang, Ming-Hong Tai, Kuei‐Sen Hsu · 2010 · Journal of Neuroscience
77. Establishment of an Immortalized Human Hepatic Stellate Cell Line to Develop Antifibrotic Therapies
    Norikuni Shibata, Takamasa Watanabe, Teru Okitsu, Masakiyo Sakaguchi, Michihiko Takesue, Takemi Kunieda, Kenji Omoto, Shinichiro Yamamoto, Noriaki Tanaka, Naoya Kobayashi · 2003 · Cell Transplantation
78. Cryo-EM structure of Saccharomyces cerevisiae target of rapamycin complex 2
    Manikandan Karuppasamy, Beata Kuśmider, Taianá Maia de Oliveira, Christl Gaubitz, Manoël Prouteau, Robbie Loewith, Christiane Schaffitzel · 2017 · Nature Communications
79. Resistance Exercise-Induced Hypertrophy: A Potential Role for Rapamycin-Insensitive mTOR
    Riki Ogasawara, Thomas E. Jensen, Craig A. Goodman, Troy Alan Hornberger · 2019 · Exercise and Sport Sciences Reviews
80. Regulation of the Rapamycin and FKBP-Target 1/Mammalian Target of Rapamycin and Cap-dependent Initiation of Translation by the c-Abl Protein-tyrosine Kinase
    Vijay Kumar, David M. Sabatini, Pramod Pandey, Anne‐Claude Gingras, Pradip K. Majumder, Madhur Kumar, Zhi-Min Yuan, Gordon Carmichael, Ralph R. Weichselbaum, Nahum Sonenberg et al. · 2000 · Journal of Biological Chemistry
81. Sanglifehrin A, a Novel Cyclophilin-Binding Immunosuppressant, Inhibits IL-2-Dependent T Cell Proliferation at the G1 Phase of the Cell Cycle
    Linghua Zhang, Jun O. Liu · 2001 · The Journal of Immunology
82. Update on Epidemiology and Therapeutics for Non-Hodgkin’s Lymphoma
    Julie Marie Vose, Brian C.‐H. Chiu, Bruce D. Cheson, Janet Ellen Dancey, John Wright · 2002 · Hematology
83. Phosphatidylinositol 3-kinase related kinases
    Robert T. Abraham · 1996 · Current Opinion in Immunology
84. U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways.
    Hidesuke Fukazawa, Yoshimasa Uehara · 2000 · PubMed
85. Nutrient and Stress Sensing in Pathogenic Yeasts
    Julian C. Rutherford, Yong‐Sun Bahn, Bert van den Berg, Joseph Heitman, Chaoyang Xue · 2019 · Frontiers in Microbiology
86. TOR: The First 10 Years
    Anja Lorberg, Michael N. Hall · 2004 · Current topics in microbiology and immunology
87. Characterization ofSaccharomyces cerevisiae dna2Mutants Suggests a Role for the Helicase Late in S Phase
    David Franklin Fiorentino, Gerald R. Crabtree · 1997 · Molecular Biology of the Cell
88. Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis
    Fen Zhang, Ting Cheng, Sheng‐Xiao Zhang · 2023 · Arthritis Research & Therapy
89. The mammalian target of rapamycin signaling network and gene regulation
    Ghada A. Soliman · 2005 · Current Opinion in Lipidology
90. Kidney-specific inactivation of Ofd1 leads to renal cystic disease associated with upregulation of the mTOR pathway
    Alessandro Zullo, Daniela Iaconis, Adriano Barra, Alessandra Cantone, Nadia Messaddeq, Giovambattista Capasso, Pascal Dollé, Peter Igarashi, Brunella Franco · 2010 · Human Molecular Genetics
91. Functional modulation of dendritic cells to suppress adaptive immune responses
    Andrea M. Woltman, Cees van Kooten · 2003 · Journal of Leukocyte Biology
92. PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells
    Camila S. Matsumoto, Luciana O. Almeida, Douglas Magno Guimarães, Manoela Domingues Martins, Pétros Papagerakis, Silvana M. Papagerakis, Andréia Machado Leopoldino, ROGERIO MORAES CASTILHO, CRISTIANE HELENA SQUARIZE · 2016 · Oncotarget
93. The ciliary protein RPGRIP1L governs autophagy independently of its proteasome-regulating function at the ciliary base in mouse embryonic fibroblasts
    Andreas Struchtrup, Antonia Wiegering, Björn Stork, Ulrich Rüther, Christoph Gerhardt · 2018 · Autophagy
94. Inhibition of Cell Cycle Progression by the Novel Cyclophilin Ligand Sanglifehrin A Is Mediated through the NFκB-dependent Activation of p53
    Ling-Hua Zhang, Hong‐Duk Youn, Jun O. Liu · 2001 · Journal of Biological Chemistry
95. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity
    M-C Liang, Jingdong Ma, Liang Chen, Piotr Kozłowski, W Qin, Dong dong Li, June Goto, Takeshi Shimamura, David Neil Hayes, Matthew M. Meyerson et al. · 2009 · Oncogene
96. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
    E. Jane Macaskill, John M.S. Bartlett, Vicky S. Sabine, Dana Faratian, Lorna Renshaw, Stephen L. White, Fiona Campbell, O. Young, Linda Jane Williams, Jeremy St J Thomas et al. · 2010 · Breast Cancer Research and Treatment
97. Current Models of Mammalian Target of Rapamycin Complex 1 (mTORC1) Activation by Growth Factors and Amino Acids
    Xu Zheng, Yan Liang, Qiburi He, Ruiyuan Yao, Wenlei Bao, Lili Bao, Yanfeng Wang, Zhigang Wang · 2014 · International Journal of Molecular Sciences
98. mTOR Complex Signaling through the SEMA4A–Plexin B2 Axis Is Required for Optimal Activation and Differentiation of CD8+ T Cells
    Daisuke Ito, Satoshi Nojima, Masayuki Nishide, Tatsusada Okuno, Hyota Takamatsu, Sujin Kang, Tetsuya Kimura, Yuji Yoshida, Keiko Morimoto, Yohei Maeda et al. · 2015 · The Journal of Immunology
99. Melatonin suppresses milk fat synthesis by inhibiting the mTOR signaling pathway via the MT 1 receptor in bovine mammary epithelial cells
    Yujuan Wang, Wenli Guo, Haichao Xu, Keqiong Tang, Linsen Zan, Wucai Yang · 2019 · Journal of Pineal Research
100. Farnesylthiosalicylic Acid Inhibits Mammalian Target of Rapamycin (mTOR) Activity Both in Cells andin Vitroby Promoting Dissociation of the mTOR-Raptor Complex
     Lloyd P. McMahon, Wei Yue, Richard J. Santen, John C. Lawrence · 2004 · Molecular Endocrinology